DKSH acquires Rocephin rights from Roche in more than 80 markets
DKSH announced it acquired rights to Roche’s Rocephin antibiotic in more than 80 markets. Rocephin generated approximately CHF 61 million in net sales in 2025.
1. Acquisition details
DKSH announced on October 28, 2026, that it acquired rights to Roche’s Rocephin antibiotic across more than 80 markets. Rocephin generated approximately CHF 61 million in net sales in 2025.
2. Portfolio expansion
The acquisition expands DKSH’s Healthcare Own Brands portfolio, following its acquisition of Meliane from Bayer, announced in July 2026.
